Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Invested Capital (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Invested Capital for 6 consecutive years, with $874714.0 as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 86.71% to $874714.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $874714.0, a 86.71% decrease, with the full-year FY2024 number at $3.7 million, up 669.42% from a year prior.
  • Invested Capital was $874714.0 for Q3 2025 at Ensysce Biosciences, down from $3.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $6.6 million in Q3 2024 to a low of -$8.2 million in Q4 2021.
  • A 5-year average of $314379.9 and a median of $1.1 million in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: tumbled 1359.15% in 2022, then soared 2344.15% in 2024.
  • Ensysce Biosciences' Invested Capital stood at -$8.2 million in 2021, then surged by 50.61% to -$4.0 million in 2022, then skyrocketed by 83.84% to -$651267.0 in 2023, then soared by 669.42% to $3.7 million in 2024, then crashed by 76.41% to $874714.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Invested Capital are $874714.0 (Q3 2025), $3.1 million (Q2 2025), and $2.7 million (Q1 2025).